If a person with Graves' disease is taking more than 1.7 mg of potassium iodide for every 1 mg of methimazole when stopping potassium iodide, their risk of thyroid hormone levels rising again in the next few weeks increases by nearly half.
Claim Context
A potassium iodide-to-methimazole daily dose ratio greater than 1.7 at the time of potassium iodide discontinuation is associated with a 49% increased odds of thyroid hormone rebound within 4–8 weeks in patients with Graves' disease, independent of free T3 levels and age.
“In a multivariate regression analysis, the levels of free T3 and the ratio of the daily dose of KI (mg) to MMI (mg) at the cessation of KI were significantly lower (p < 0.0001, p = 0.0007) in patients without deterioration than in those with deterioration. The odds ratios were 0.175 (95% confidence interval [CI]: 0.072–0.381) and 0.675 (95% CI: 0.533–0.846), respectively.”
Evidence from Studies
No evidence studies found yet.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Whether the KI/MMI ratio threshold of 1.7 is consistently predictive of rebound across different clinical settings, dosing regimens, and patient populations.
A systematic review and meta-analysis pooling individual patient data from all prospective studies evaluating KI/MMI ratios at discontinuation, using regression models to determine the optimal predictive ratio for rebound, adjusting for baseline T4, TRAb, and treatment duration.
Whether deliberately maintaining a KI/MMI ratio ≤1.7 at discontinuation causally reduces rebound risk compared to higher ratios.
A double-blind RCT of 300 Graves' patients on KI/MMI, randomized to discontinue KI when KI/MMI ratio is ≤1.7 (intervention) vs. when ratio is >1.7 (control), with primary outcome: rebound (free T3 >4.3 pg/mL) at 6 weeks, controlling for baseline T4 and TRAb.
Whether the KI/MMI ratio at discontinuation prospectively predicts rebound in a larger, real-world population.
A prospective cohort study of 600+ Graves' patients initiating KI/MMI, with daily dose recording and KI discontinued when T4 normalizes; primary outcome: rebound within 8 weeks, analyzed by KI/MMI ratio at discontinuation, adjusting for free T3, age, and TRAb.
Whether patients who rebounded had significantly higher KI/MMI ratios at discontinuation than those who did not.
A case-control study comparing 120 patients with rebound within 8 weeks of KI discontinuation to 120 matched controls without rebound, measuring KI and MMI doses at the exact time of discontinuation and calculating the ratio.
Whether KI/MMI ratio at discontinuation correlates with subsequent hormone levels in a single snapshot.
A cross-sectional analysis of 300 Graves' patients at KI discontinuation, measuring KI and MMI doses to calculate ratio, then measuring free T3 and T4 6 weeks later without intervention, to assess correlation.